Rhythm Pharma CMO resigns; new CMO appointed; updated Phase 3 data on setmelanotide

RHYTHM PHARMACEUTICALS, INC.

Dr. Murray Stewart resigns as CMO effective Sept 10, 2021; will serve as Senior Medical Advisor for up to one year at $12,000/month.
Linda Shapiro Manning, M.D., Ph.D., appointed as new CMO effective Sept 10; previously SVP Clinical.
Updated slide presentation includes new BMI reduction data from Phase 3 Bardet-Biedl syndrome trial and EMANATE powering assumptions.
Stewart's vested options remain exercisable 3 months post-consulting; unvested options forfeited; RSUs continue vesting.
Stewart eligible for prorated 2021 annual bonus based on employment and part-time consulting.

item 5.02 item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Linda Shapiro Manning

Chief Medical Officer

RYTM · RHYTHM PHARMACEUTICALS, INC.

Effective: 2021-09-10
Filed: September 2, 2021, 7:59 PM ET

The Board has appointed Linda Shapiro Manning, M.D., Ph.D., currently Senior Vice President, Clinical of the Company, to succeed Dr. Stewart as Chief Medical Officer as of the Effective Date.

Departed

Murray Stewart

Chief Medical Officer

RYTM · RHYTHM PHARMACEUTICALS, INC.

Effective: 2021-09-10
Successor: Linda Shapiro Manning
Filed: September 2, 2021, 7:59 PM ET

On August 31, 2021, Murray Stewart, D.M., F.R.C.P. notified Rhythm Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Medical Officer, effective as of September 10, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Linda Shapiro Manning was appointed as Chief Medical Officer at RHYTHM PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

The Board has appointed Linda Shapiro Manning, M.D., Ph.D., currently Senior Vice President, Clinical of the Company, to succeed Dr. Stewart as Chief Medical Officer as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Murray Stewart resigned as Chief Medical Officer at RHYTHM PHARMACEUTICALS, INC..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On August 31, 2021, Murray Stewart, D.M., F.R.C.P. notified Rhythm Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Medical Officer, effective as of September 10, 2021

View on SEC.gov

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-21-112483

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.